GTx (NASDAQ: GTXI) and Blueprint Medicines Corporation (NASDAQ:BPMC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Earnings and Valuation
This table compares GTx and Blueprint Medicines Corporation’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Blueprint Medicines Corporation||$25.58 million||98.83||-$99.21 million||($3.07)||-21.05|
GTx has higher revenue, but lower earnings than Blueprint Medicines Corporation. Blueprint Medicines Corporation is trading at a lower price-to-earnings ratio than GTx, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
GTx has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Blueprint Medicines Corporation has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for GTx and Blueprint Medicines Corporation, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Blueprint Medicines Corporation||0||0||9||0||3.00|
Blueprint Medicines Corporation has a consensus price target of $63.47, suggesting a potential downside of 1.79%. Given Blueprint Medicines Corporation’s higher probable upside, analysts plainly believe Blueprint Medicines Corporation is more favorable than GTx.
Institutional and Insider Ownership
9.1% of GTx shares are owned by institutional investors. Comparatively, 90.7% of Blueprint Medicines Corporation shares are owned by institutional investors. 41.2% of GTx shares are owned by company insiders. Comparatively, 3.4% of Blueprint Medicines Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares GTx and Blueprint Medicines Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Blueprint Medicines Corporation||-388.91%||-45.58%||-34.66%|
Blueprint Medicines Corporation beats GTx on 6 of the 11 factors compared between the two stocks.
GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.
About Blueprint Medicines Corporation
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.